Thomas, Rintu, Srivastava, Shivangi, Katreddy, Rajasekhara Reddy, Sobieski, Jason, Weihua, Zhang (2019) Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences, 20. 2515pp. doi:10.3390/ijms20102515

See Also

These are possibly similar items as determined by title/reference text matching only.

	Mallmann-Gottschalk, Nina, Sax, Yvonne, Kimmig, Rainer, Lang, Stephan, Brandau, Sven (2019) EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. International Journal of Molecular Sciences, 20. 4693pp. doi:10.3390/ijms20194693
	Shao, Hanshuang; Wells, Alan (2025) Evaluating the Effectiveness of Tyrosine Kinase Inhibitors on EGFR Mutations In Vitro. International Journal of Molecular Sciences, 26 (13). doi:10.3390/ijms26136157
	Russo, Alessandro, Franchina, Tindara, Ricciardi, Giuseppina, Battaglia, Alessandra, Picciotto, Maria, Adamo, Vincenzo (2019) Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. International Journal of Molecular Sciences, 20. 1431pp. doi:10.3390/ijms20061431
	Kobayashi, Keigo, Tan, Aaron C. (2023) Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. International Journal of Molecular Sciences, 24 (4) 4126 doi:10.3390/ijms24044126
	Lee, Ching-Yi, Lee, Shih-Wei, Hsu, Yi-Chiung (2025) Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences, 26 (5). doi:10.3390/ijms26052042
	Yemini-Talbi, Odeya; Nir, Uri; Breitbart, Haim (2025) The Fer Tyrosine Kinase Mediates EGFR Activation in Sperm Capacitation. International Journal of Molecular Sciences, 26 (22). doi:10.3390/ijms262211218
	Lee, Jeon-Soo, Choi, Young Eun, Kim, Sunshin, Han, Ji-Youn, Goh, Sung-Ho (2021) ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί. International Journal of Molecular Sciences, 22 (22) 12287pp. doi:10.3390/ijms222212287
	Anakura, Mai, Nachankar, Ankita, Kobayashi, Daijiro, Amornwichet, Napapat, Hirota, Yuka, Shibata, Atsushi, Oike, Takahiro, Nakano, Takashi (2019) Radiosensitivity Differences between EGFR Mutant and Wild-Type Lung Cancer Cells are Larger at Lower Doses. International Journal of Molecular Sciences, 20. 3635pp. doi:10.3390/ijms20153635
	Glowacki, Sylwester, Synowiec, Ewelina, Blasiak, Janusz (2013) The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences, 14. 16348-16364 doi:10.3390/ijms140816348
	Yonesaka, Kimio, Iwama, Eiji, Hayashi, Hidetoshi, Suzuki, Shinichiro, Kato, Ryoji, Watanabe, Satomi, Takahama, Takayuki, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Sakai, Kazuko, Azuma, Koichi, Chiba, Yasutaka, Atagi, Shinji, Nishio, Kazuto, Okamoto, Isamu, Nakagawa, Kazuhiko (2019) Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Scientific Reports, 9. doi:10.1038/s41598-019-55939-5
	Lowder, Melissa A., Doerner, Amy E., Schepartz, Alanna (2015) Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors. Journal Of The American Chemical Society, 137 (20) 6456-6459 doi:10.1021/jacs.5b02326